bpc-157 clinical trials human dosing trial Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal Gray market peptides blur drug – Doctors are using a regulatory

(PMID: 15531385), rats given BPC-157 0.0045 mg/lb showed significantly elevated serotonin synthesis in the substantia nigra reticulata and medial anterior olfactory nucleus following acute administration

The theoretical concern remains unconfirmed in humans but is biologically plausible given the peptide's pro-vascular activity

Hepatology 35 , 217223 (2002)

This allows the vial to be used for multiple withdrawals over a limited period when handled properly

PE-22-28 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use

Doping used to be something just for athletes, but now performance enhancing drugs are available to anyone even those who have no idea what they are using isnt legal or subject to any specific categorization by the FDA nor any meaningful quality control standards